Methylphenidate HCl: therapy for attention deficit hyperactivity disorder

References

• Pelham WE Jr, Greenslade KE, Vodde-Hamilton M et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86(2), 226–237 (1990).
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 23(10), 1281–1299 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang J, Deng Y, Fang J, McKay G. Enantioselective analysis of ritalinic acids in biological samples by using a protein-based chiral stationary phase. Pharm. Res. 20(11), 1881–1884 (2003).
   PubMed Web of Science ®Google Scholar
• Sane N, McGough JJ. MethyPatch Noven. Curr. Opin. Investig. Drugs 3(8), 1222–1224 (2002).
   PubMedGoogle Scholar
• Hubbard JW, Srinivas NR, Quinn D, Midha KK. Enantioselective aspects of the disposition of D,L-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. J. Pharm. Sci. 11, 944–947 (1989).
   Google Scholar
• Redalieu E, Bartlett MF, Waldes LM et al. A study of methylphenidate in man with respect to its major metabolite. Drug Metab. Dispos. 10, 708–709 (1982).
   PubMed Web of Science ®Google Scholar
• Ding YS, Gatley SJ, Thanos PK et al. Brain kinetics of methylphenidate (Ritalin®) enantiomers after oral administration. Synapse 53(3), 168–175 (2004).
   PubMed Web of Science ®Google Scholar
• Faraj BA, Israili ZH, Perel JM et al. Metabolism and disposition of methylphenidate-14C: studies in man and animals. J. Pharmacol. Exp. Ther. 191, 535–547 (1974).
   PubMed Web of Science ®Google Scholar
• Srinivas NR, Hubbard JW, Quinn D, Midha KK. Enantio-selective pharmacokinetics and pharmacodynamics of D,L-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin. Pharmacol. Ther. 52, 561–568 (1992).
   PubMed Web of Science ®Google Scholar
• Sun Z, Murry DJ, Sanghani SP et al. Methylphenidate is stereoselectively hydrolyzed by human caboxylesterase CES1A1. J. Pharmacol. Exp. Ther. 310(2), 469–476 (2004).
   PubMed Web of Science ®Google Scholar
• Bartlik B, Harmon G. Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma. Arch. Gen. Psychiatry. 54, 188–189 (1997).
   PubMed Web of Science ®Google Scholar
• Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J. Clin. Psychiatry 65, 1520–1524 (2004).
   PubMed Web of Science ®Google Scholar
• Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58, 527–536 (2002).
   PubMed Web of Science ®Google Scholar
• Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J. Child Adolesc. Psychpharmacol. 14, 185–194 (2004).
   PubMed Web of Science ®Google Scholar
• Ahmann P, Waltonen S, Olson K, Theye F, Van Erem A, LaPlant R. Placebo-controlled evaluation of ritalin side effects. Pediatrics 91(6), 1101–1106 (1993).
   PubMed Web of Science ®Google Scholar
• Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 86(2), 184–192 (1990).
   PubMed Web of Science ®Google Scholar
• Efron D, Jarma F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100, 662–666 (1997).
   PubMed Web of Science ®Google Scholar
• Lisska MC, Rivkees SA. Daily methylphenidate use slows the growth of children: a community based study. J. Pediatr. Endocrinol. Metab. 16(5), 711–718 (2003).
   PubMed Web of Science ®Google Scholar
• Rapport MD, Moffitt C. Attention deficit hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin. Psychol. Rev. 22(8), 1107–1131 (2002).
   PubMed Web of Science ®Google Scholar
• Toren P, Silbergeld A, Eldar S et al. Lack of effect of methylphenidate on serum growth hormone (GH), GH-binding protein, and insulin-like growth factor I. Clin. Neuropharmacol. 20(3), 264–269 (1997).
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113, 762–769 (2004).
   PubMed Web of Science ®Google Scholar
• Tan M, Appleton R. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy. Arch. Dis. Childhood. 90, 57–59 (2005).
   PubMed Web of Science ®Google Scholar
• Biederman J. Pharmacotherapy for attention deficit hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J. Clin. Psychiatry 64(Suppl. 11), 3–8 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescent patients with co-occurring ADHD and substance dependence. J. Addic. Dis. 23, 31–40 (2004).
   PubMed Web of Science ®Google Scholar
• Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci. Biobehav. Rev. 27, 615–621 (2003).
   PubMed Web of Science ®Google Scholar
• Brandon CL, Marinelli M, White FJ. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biol. Psych. 54, 1338–1344 (2003).
   PubMed Web of Science ®Google Scholar
• Wax PM. Analeptic use in clinical toxicology: a historical appraisal. J. Toxicol. Clin. Toxicol. 35, 203–209 (1997).
   PubMed Web of Science ®Google Scholar
• Loo SK, Specter E, Smolen A et al. Functional effects of the DAT1 polymorphism on EEG measures in ADHD. J. Am. Acad. Child Adolesc. Psychiatry 42(8), 986–993 (2003).
   PubMed Web of Science ®Google Scholar
• Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354, 2132–2133 (1999).
   PubMed Web of Science ®Google Scholar
• Krause KH, Dresel SH, Krause J et al. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci. Biobehav. Rev. 27(7), 605–613 (2003).
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Quinlan DM, Cretalla LM et al. Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am. J. Psychiatry 159, 309–312 (2002).
   PubMed Web of Science ®Google Scholar
• Langley K, Marshall L, van den Bree M et al. Association of the dopamine D4 receptor gene 7-repeat allele with neuropsychological test performance of children with ADHD. Am. J. Psychiatry 161(1), 133–138 (2004).
   PubMed Web of Science ®Google Scholar
• LaHoste GJ, Swanson JM, Wigal SB et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry. 1(2), 121–124 (1996).
   PubMed Web of Science ®Google Scholar
• Faraone SV, Doyle AE, Mick E, Biederman J. Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. Am. J. Psychiatry 158(7), 1052–1057 (2001).
   PubMed Web of Science ®Google Scholar
• Avale ME, Falzone TL, Gelman DM et al. The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder. Mol. Psychiatry 9(7), 718-26 (2004).
   Google Scholar
• Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J. Neurosci. 22(19), 8705–8710 (2002).
   PubMed Web of Science ®Google Scholar
• Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther. 304(3), 1181–1187 (2003).
   PubMed Web of Science ®Google Scholar
• Davids E, Zhang K, Kula NS et al. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J. Pharmacol. Exp. Ther. 301(3), 1097–1102 (2002).
   PubMed Web of Science ®Google Scholar
• Overtoom CC, Verbaten MN, Kemner C et al. Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder. Behav. Brain Res. 145(1–2), 7–15 (2003).
   PubMed Web of Science ®Google Scholar
• Barrickman LL, Perry P, Allen A et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 34(5), 649–657 (1995).
   PubMed Web of Science ®Google Scholar
• Kratochvil CJ, Vaughan BS, Harrington MJ, et al. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Pharmacother. 4, 1165–1174 (2003).
   PubMed Web of Science ®Google Scholar
• Schweri M, Skolnick P, Rafferty M et al. [3H]Threo-(±)-methylphenidate binding to 3,4-dihydrophenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J. Neurochem. 45(4), 1062–1070 (1985).
   PubMed Web of Science ®Google Scholar
• Szobot CM, Ketzer C, Cunha RD et al. The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit hyperactivity disorder. Eur. J. Nucl. Med. Mol. Imaging 30(3), 423–426 (2003).
   PubMed Web of Science ®Google Scholar
• Morecraft RJ, Geula C, Mesulam MM. Architecture of connectivity within a cingulo-fronto-parietal neurocognitive network for directed attention. Arch. Neurol. 50(3), 279–284 (1993).
   PubMed Web of Science ®Google Scholar
• Mattay VS, Berman KF, Ostrem JL et al. Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study. J. Neurosci. 16(15), 4816–4822 (1996).
   PubMed Web of Science ®Google Scholar
• Mehta MA, Goodyer IM, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J. Child Psychol. Psyc. 45(2), 293–305 (2004).
   PubMed Web of Science ®Google Scholar
• Tannock R, Ickowicz A, Schachar R. Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J. Am. Acad.Child Adolesc. Psychiatry 34(7), 886–896 (1995).
   PubMed Web of Science ®Google Scholar
• Wolraich M, Greenhill L, Pelham W et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108(4), 883–892 (2001).
   PubMed Web of Science ®Google Scholar
• Stein MA, Sarampote CS, Waldman ID et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112(5), e404 (2003).
   Google Scholar
• Swanson JM, Wigal SB, Wigal T et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics 113(3 Pt 1), e206–e216 (2004).
   PubMed Web of Science ®Google Scholar
• Lopez F, Silva R, Pestreich L et al. Comparative efficacy of two once-daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr. Drugs 5, 545–555 (2003).
   PubMedGoogle Scholar
• Wigal S, Swanson JM, Feifel D. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and D,L-threo-methylphenidate hydrochloride in children with attention deficit/hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psych. 43, 1406–1414 (2004).
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for Attention-Deficit/Hyperactivity Disorder. Arch. Gen. Psychiatry 56(12), 1073–1086 (1999).
   PubMed Web of Science ®Google Scholar
• Greenhill L, Swanson J, Vitiello B et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J. Am. Acad. Child Adolesc. Psychiatry 40(2), 180–187 (2001).
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24 month outcomes of treatment strategies for Attention-Deficit/Hyperactivity Disorder. Pediatrics 113(4), 754–761 (2004).
   PubMed Web of Science ®Google Scholar
• Conners CK, Epstein JN, March JS et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J. Am. Acad. Child. Adolesc. Psychiatry 40(2), 159–167 (2001).
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol. Psych. 57, 456–463 (2005).
   PubMed Web of Science ®Google Scholar
• GucuyenerK, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kockar AI. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J. Child. Neurol. 18, 109–112 (2003).
   PubMed Web of Science ®Google Scholar